

Evaluation Report for Category B, Subcategory 2.4 Application

Application Number: 2021-3416

Application: Changes EP Chemistry – Proportion of Formulants

Product: SERENADE ASO

Registration Number: 28628

Active ingredient (a.i.): Bacillus subtilis (strain QST 713)

PMRA Document Number: 3333094

Purpose of Application

The purpose of this application was to add an alternate formulation and to make minor amendments to the formulation process for SERENADE ASO.

Product Characterization and Analysis

Sufficient batch analysis data for potency estimation, microbial contamination, storage stability, and physical and chemical properties were submitted to support the registration of a minor amendment to the formulation process and an alternate formulation for SERENADE ASO.

Health Assessments

SERENADE ASO produced using the amended formulation process and the alternate formulation are considered to be biologically equivalent to the existing registered end-use product. As the human health and safety database for the active ingredient, *Bacillus subtilis* strain QST 713, and SERENADE ASO is considered complete, no additional information is required.

Environmental Assessment

SERENADE ASO produced using the amended formulation process and the alternate formulation are considered to be biologically equivalent to the existing registered end-use product. As the environmental toxicology database for the active ingredient, *Bacillus subtilis* strain QST 713, and SERENADE ASO is considered complete, no additional information is required.

Value Assessment

Based on the available information, the formulation differences between the alternate formulation and the registered formulation of SERENADE ASO are unlikely to result in differences in product performance. Therefore, the registration of an alternate formulation is supported from a value perspective.



Conclusion

The Pest Management Regulatory Agency has completed an assessment of the available information and has found it sufficient to support the addition of an alternate formulation and minor amendments to the formulation process for SERENADE ASO.

References

PMRA References	
Document	
Number	
3319093 2020, Manufacturing process for Serenade ASO for Canada, DACO: Manufacturing process for Serenade AS	И2.8 CBI
3319094 2020, Material accountability study - 5 batch analysis of Serenade ASC	O, DACO:
M2.9.2 CBI	
3319092 2020, Serenade ASO: Accelerated storage stability, DACO: M2.11 CB	BI

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health Canada, 2022

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.